Agilon Health, Inc. (NYSE:AGL – Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 24,591,484 shares, a growth of 20.5% from the February 12th total of 20,413,986 shares. Based on an average daily trading volume, of 7,495,718 shares, the short-interest ratio is presently 3.3 days. Approximately 6.1% of the shares of the company are sold short. Approximately 6.1% of the shares of the company are sold short. Based on an average daily trading volume, of 7,495,718 shares, the short-interest ratio is presently 3.3 days.
Agilon Health Stock Performance
NYSE AGL opened at $0.61 on Wednesday. The stock has a market capitalization of $254.73 million, a price-to-earnings ratio of -0.65 and a beta of 0.11. The business’s 50 day moving average is $0.69 and its two-hundred day moving average is $0.80. Agilon Health has a 12-month low of $0.34 and a 12-month high of $6.08. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12.
Agilon Health (NYSE:AGL – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.19). Agilon Health had a negative net margin of 6.60% and a negative return on equity of 120.82%. The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.46 billion. Research analysts expect that Agilon Health will post -0.59 EPS for the current year.
Hedge Funds Weigh In On Agilon Health
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on AGL shares. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Royal Bank Of Canada raised Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a report on Wednesday, January 21st. Wells Fargo & Company lifted their price objective on shares of Agilon Health from $1.00 to $1.50 and gave the company an “overweight” rating in a research report on Friday, February 27th. Finally, Barclays dropped their price objective on shares of Agilon Health from $1.00 to $0.50 and set an “underweight” rating on the stock in a research note on Friday, February 27th. Three investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $2.18.
Check Out Our Latest Report on Agilon Health
About Agilon Health
Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.
Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.
Further Reading
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
